USD 0.19
(8.7%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - USD | -100.0% |
2022 | 152.43 Thousand USD | -49.11% |
2021 | 299.52 Thousand USD | -39.34% |
2020 | 493.79 Thousand USD | -26.38% |
2019 | 670.69 Thousand USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 FY | - USD | -100.0% |
2023 Q1 | 104.46 Thousand USD | -31.47% |
2023 Q2 | 65.75 Thousand USD | -37.06% |
2023 Q3 | - USD | -100.0% |
2022 Q1 | 253.92 Thousand USD | -15.22% |
2022 Q3 | 204.59 Thousand USD | -5.87% |
2022 FY | 152.43 Thousand USD | -49.11% |
2022 Q4 | 152.43 Thousand USD | -25.49% |
2022 Q2 | 217.35 Thousand USD | -14.4% |
2021 Q4 | 299.52 Thousand USD | -14.23% |
2021 FY | 299.52 Thousand USD | -39.34% |
2021 Q3 | 349.19 Thousand USD | -12.3% |
2021 Q2 | 398.17 Thousand USD | -10.82% |
2021 Q1 | 446.46 Thousand USD | -9.58% |
2020 Q4 | 493.79 Thousand USD | -8.45% |
2020 FY | 493.79 Thousand USD | -26.38% |
2020 Q3 | 539.38 Thousand USD | -7.62% |
2020 Q2 | 583.86 Thousand USD | -6.99% |
2020 Q1 | 627.72 Thousand USD | -6.41% |
2019 FY | 670.69 Thousand USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | 616.15 Thousand USD | 0.0% |
2019 Q3 | 586.17 Thousand USD | -4.87% |
2019 Q4 | 670.69 Thousand USD | 14.42% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2017 Q2 | 2.4 Million USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | -100.0% |
2017 Q3 | 2.4 Million USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q2 | 2.05 Million USD | 165.67% |
2012 Q1 | 773.9 Thousand USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q3 | - USD | -100.0% |
2011 Q2 | 4.5 Million USD | 50.0% |
2011 FY | - USD | 0.0% |
2011 Q1 | 3 Million USD | 0.0% |
2011 Q3 | - USD | -100.0% |
2011 Q4 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2005 Q3 | - USD | -100.0% |
2005 Q4 | - USD | 0.0% |
2005 Q2 | 374.26 Thousand USD | 2.96% |
2005 FY | - USD | 0.0% |
2005 Q1 | 363.5 Thousand USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | - USD | NaN% |
Armata Pharmaceuticals, Inc. | 82.3 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | 1.57 Million USD | 100.0% |
Azitra, Inc. | 563.69 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 13 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | - USD | NaN% |
Calidi Biotherapeutics, Inc. | 2.06 Million USD | 100.0% |
CEL-SCI Corporation | 11.6 Million USD | 100.0% |
iBio, Inc. | 3.5 Million USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 100.0% |
MAIA Biotechnology, Inc. | - USD | NaN% |
Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | 100.0% |
NanoViricides, Inc. | - USD | NaN% |
BiomX Inc. | 5.4 Million USD | 100.0% |
BiomX Inc. | 5.4 Million USD | 100.0% |
Protalix BioTherapeutics, Inc. | 4.62 Million USD | 100.0% |
Palatin Technologies, Inc. | 163.78 Thousand USD | 100.0% |
Scorpius Holdings, Inc. | 12.61 Million USD | 100.0% |
Theriva Biologics, Inc. | 162 Thousand USD | 100.0% |